Stada's Sales Grow Double Digits In 2021
Executive Summary
Stada strengthened its position as Europe's fourth-largest OTC player in 2021 as sales at its Consumer Healthcare business jumped by 15%.
You may also be interested in...
Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
Stada Expands Portfolio In US And Nordics As First-Half Sales Rise
Stada reported Branded Products sales up 9% in the first half as it secured two additions to its portfolio, with a US dietary supplement brand and Nordic herbal analgesic.
Stada To Market 50 Sanofi Brands Across Europe
Germany's Stada is strengthening its portfolio by taking over distribution of 50 well-established Sanofi Consumer Healthcare brands marketed across Europe.